Helen Torley joins Onyx Pharmaceuticals

Takes the position of executive vp and chief commercial officer

Californian biopharmaceutical firm Onyx Pharmaceuticals has appointed Helen Torley as executive vice president and chief commercial officer.

Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.

Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.

From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.

Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.

You may also like

Finance

Amgen to buy Onyx Pharmaceuticals for US$10.4bn

Onyx pipeline complements oncology portfolio of Amgen
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now